$JANX

Janux Therapeutics, Inc. (JANX): Submission of Matters to a Vote of Security Holders

Janux Therapeutics, Inc. (JANX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001817713 0001817713 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11,

Original reporting
Published Jun 12, 2026, 8:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$JANX
Neutral
high confidence
Mentioned
$JANX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$JANXNeutralLow
01

Why it matters

Confirms governance items: two Class II directors elected, Ernst & Young LLP ratified as independent auditor for FY2026, and advisory approval of executive compensation.

02

Market read

This is a routine post-meeting disclosure; it does not introduce new operating, clinical, or financial information.

03

What to watch

Traders may instead focus on upcoming catalysts (e.g., trial readouts or financing) not covered in this 8-K.

Relevance 6/10Novelty 2/10Timing: Filed June 12, 2026 for June 11 annual meeting results

Background

The SEC 8-K (Item 5.07) reports matters submitted to a vote of security holders at Janux’s 2026 annual meeting on June 11, 2026.

Company-level read

Ticker impact

$JANXNeutralHigh confidence
Context

Janux Therapeutics filed an 8-K detailing 2026 annual meeting voting results, including director elections and advisory say-on-pay approval.

Expected impact

Low near-term impact; any reaction would be sentiment/flow-driven rather than fundamental.

Evidence & confidence

The filing reports election/ratification/advisory vote tallies without new financial guidance, clinical/regulatory updates, or transactions.

Market effects

Minimal; governance vote outcomes do not reset biotech sector risk or expectations.

None indicated; US-listed microcap governance filing only.

None indicated.

Counterpoint

If the vote results were unusually contentious, it could hint at shareholder dissatisfaction, but the article provides no narrative on dissent beyond vote counts.

Key entities

  • Janux Therapeutics, Inc.

    Company filing the 8-K and reporting annual meeting voting results.

  • Natasha Hernday

    Elected as Class II director (votes for/withheld and broker non-votes reported).

  • Eric Dobmeier

    Elected as Class II director (votes for/withheld and broker non-votes reported).

  • Ernst & Young LLP

    Ratified by stockholders as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.

Related articles

$JANXLow

Janux Therapeutics Doses First Patient In Phase 1 Study Of JANX013

Janux Therapeutics (JANX) dosed the first patient in a Phase 1 trial for JANX013, a treatment for metastatic castration-resistant prostate cancer (mCRPC), in combination with JANX007. The study will evaluate safety, tolerability, and preliminary efficacy. JANX013 aims to enhance anti-tumor immune responses. JANX stock is up 1.81% at $17.41.

$JANXMed

Janux Therapeutics, Inc. (JANX): Results of Operations and Financial Condition

Janux Therapeutics, Inc. (JANX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights • JANX007 Phase 1b enrollment continues across taxane-naïve monotherapy and darolutamide combination cohorts • JANX014 Phase 1 study continues enrolling patients with metastatic